The AE categories with lower incidence for both nilotinib 300mg BID and 400mg BID versus imatinib 400mg daily were gastrointestinal , blood and lymphatic system , and musculoskeletal ; nilotinib 300mg BID had lower incidence than imatinib for general disorders .